DEVELOPMENTAL CELL BIOLOGY OF DENDRITIC CELLS

树突状细胞的发育细胞生物学

基本信息

  • 批准号:
    2822533
  • 负责人:
  • 金额:
    $ 30.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-03-01 至 2003-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from the Investigator's abstract): Dendritic cells (DCs) play a central role in the immune response due to their capacity for presenting antigens to present antigens to naive T-lymphocytes. Despite their importance, relatively little is known concerning the cell biology, development, or functions of this highly specialized cell type. Recent evidence has demonstrated that DCs can be induced by inflammatory stimuli to exhibit a remarkable developmental pattern accompanied by striking changes in cell morphology, surface expression of MHC class II, endocytosis, and the capacity for antigen presentation. These changes reflect the functional states characteristic of DCs at different stages of their life cycle, during which DCs first reside in peripheral tissues where they act as sentinels that accumulate but are unable to present foreign antigens, and then migrate to lymphoid organs where they can present their accumulated antigens to T-cells. We now plan to determine the cellular and molecular mechanisms responsible for DC maturation, and to elucidate how these alterations result in the conversion of DCs form cells actively engaged in antigen accumulation to cells uniquely well adapted for antigen presentation. The application proposes four Specific Aims: 1. To characterize in detail the three distinct stages in dendritic cell development in mouse bone marrow-derived DCs, and to extend these results to human DCs cultured from CD34+ precursors both to generalize our conclusions and to provide sufficient material for biochemical analysis. 2. To characterize the features and biogenesis of novel MHC class II-containing compartments in DCs, including compartment likely to be involved in antigen processing as well as unique, DC-specific compartments of no known function (e.g., Birbeck granules). 3. To elucidate the mechanisms controlling the surface expression of MHC class II molecules and various accessory proteins during DC development. In the case of class II molecules, initial suggest that the developmentally regulated cleavage of invariant chain plays a key role in controlling class II expression by controlling the intracellular transport of class II. 4. To correlate alterations in DC development with the regulation of antigen processing and presentation by DCs. The application will investigate how the regulation of class II transport, endocytosis, and accessory molecule expression determine antigen processing and presentation activities.
描述(改编自研究者摘要):树突状细胞

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IRA S MELLMAN其他文献

IRA S MELLMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IRA S MELLMAN', 18)}}的其他基金

Research Programs-Immunology and Immunotherapy
研究项目-免疫学和免疫治疗
  • 批准号:
    7513241
  • 财政年份:
    2007
  • 资助金额:
    $ 30.22万
  • 项目类别:
Developmental Funds
发展基金
  • 批准号:
    7513171
  • 财政年份:
    2007
  • 资助金额:
    $ 30.22万
  • 项目类别:
Cell Biology of the Immune Response
免疫反应的细胞生物学
  • 批准号:
    6583493
  • 财政年份:
    2003
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6591256
  • 财政年份:
    2002
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6570936
  • 财政年份:
    2002
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6594411
  • 财政年份:
    2002
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6571155
  • 财政年份:
    2002
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6437378
  • 财政年份:
    2001
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6435828
  • 财政年份:
    2001
  • 资助金额:
    $ 30.22万
  • 项目类别:
CONTROL OF CELL POLARITY & PLASMA MEMBRANE FUNCTION BY RHO FAMILY GTPASE
电池极性的控制
  • 批准号:
    6430849
  • 财政年份:
    2001
  • 资助金额:
    $ 30.22万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 30.22万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 30.22万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 30.22万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 30.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 30.22万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 30.22万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 30.22万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 30.22万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 30.22万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 30.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了